JBIO

Company Overview — What Does Aerovate Therapeutics, Inc. Do?

Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. Aerovate Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts. Aerovate Therapeutics, Inc. (JBIO) is classified as a small-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Timothy P. Noyes and employs approximately 20 people. With a market capitalization of $790M, JBIO is one of the notable companies in the Healthcare sector.

Aerovate Therapeutics, Inc. (JBIO) Stock Rating — Hold (April 2026)

As of April 2026, Aerovate Therapeutics, Inc. receives a Hold rating with a composite score of 33.7/100 and 3 out of 5 stars from the Blank Capital Research quantitative model.JBIO ranks #1,210 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Aerovate Therapeutics, Inc. ranks #91 of 838 stocks, placing it in the top quartile of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

JBIO Stock Price and 52-Week Range

Aerovate Therapeutics, Inc. (JBIO) currently trades at $17.70. The stock lost $0.53 (2.9%) in the most recent trading session. The 52-week high for JBIO is $17.71, which means the stock is currently trading -0.1% from its annual peak. The 52-week low is $2.44, putting the stock 625.4% above its annual trough. Recent trading volume was 328K shares, suggesting relatively thin trading activity.

Is JBIO Overvalued or Undervalued? — Valuation Analysis

Aerovate Therapeutics, Inc. (JBIO) carries a value factor score of 21/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 2.43x, versus the sector average of 2.75x.

At current multiples, Aerovate Therapeutics, Inc. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

Aerovate Therapeutics, Inc. Profitability — ROE, Margins, and Quality Score

Aerovate Therapeutics, Inc. (JBIO) earns a quality factor score of 22/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -22.9%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -21.8% versus the sector average of -33.1%.

Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

JBIO Debt, Balance Sheet, and Financial Health

Aerovate Therapeutics, Inc. has a debt-to-equity ratio of 5.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 21.09x, indicating strong short-term liquidity. Total debt on the balance sheet is $0. Cash and equivalents stand at $50M.

JBIO has a beta of 1.04, meaning it is roughly in line with the broader market in terms of price volatility. The stability factor score for Aerovate Therapeutics, Inc. is 24/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

Aerovate Therapeutics, Inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, Aerovate Therapeutics, Inc. reported revenue of $0 and earnings per share (EPS) of $-3.19. Net income for the quarter was $-76M. Operating income came in at $-74M.

In FY 2025, Aerovate Therapeutics, Inc. reported revenue of $0 and earnings per share (EPS) of $-3.19. Net income for the quarter was $-127M. Operating income came in at $-114M.

In Q3 2025, Aerovate Therapeutics, Inc. reported revenue of $0 and earnings per share (EPS) of $-0.48. Net income for the quarter was $-25M. Operating income came in at $-27M.

In Q2 2025, Aerovate Therapeutics, Inc. reported revenue of $0 and earnings per share (EPS) of $-0.86. Net income for the quarter was $-32M. Operating income came in at $-28M.

Over the past 8 quarters, Aerovate Therapeutics, Inc. has experienced revenue contraction from $0 to $0. Investors analyzing JBIO stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

JBIO Dividend Yield and Income Analysis

Aerovate Therapeutics, Inc. (JBIO) currently pays a dividend yield of 27.8%. At this yield, a $10,000 investment in JBIO stock would generate approximately $$2781.00 in annual dividend income.

JBIO Momentum and Technical Analysis Profile

Aerovate Therapeutics, Inc. (JBIO) has a momentum factor score of 71/100, indicating strong price momentum with the stock outperforming the majority of the market over recent periods. Stocks with high momentum scores have historically tended to continue their outperformance in the near term. The investment factor score is 25/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 14/100 signals elevated short interest, which can indicate bearish sentiment among institutional investors.

JBIO vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, Aerovate Therapeutics, Inc. (JBIO) ranks #91 out of 838 stocks based on the Blank Capital composite score. This places JBIO in the top quartile of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing JBIO against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full JBIO vs S&P 500 (SPY) comparison to assess how Aerovate Therapeutics, Inc. stacks up against the broader market across all factor dimensions.

JBIO Next Earnings Date

No upcoming earnings date has been announced for Aerovate Therapeutics, Inc. (JBIO) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy JBIO? — Investment Thesis Summary

Aerovate Therapeutics, Inc. presents a balanced picture with arguments on both sides. The quality score of 22/100 flags below-average profitability. The value score of 21/100 indicates premium valuation. Price momentum is positive at 71/100, suggesting the trend favors buyers. High volatility (stability score 24/100) increases portfolio risk.

In summary, Aerovate Therapeutics, Inc. (JBIO) earns a Hold rating with a composite score of 33.7/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on JBIO stock.

Related Resources for JBIO Investors

Explore more research and tools: JBIO vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare JBIO head-to-head with peers: JBIO vs AZN, JBIO vs SLGL, JBIO vs VMD.